{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.02","upperLimit":"0.18","value":"0.07"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"0.21","value":"0.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"Evaluation of cytogenetic response requires 20 analyzable metaphases when using conventional techniques. Analysis of data will require 20 metaphases before and after treatment, which must be done on bone marrow only (peripheral blood is not a substitute). Fluorescent in situ hybridization (FISH) may be used as a supplement to follow a specifically defined cytogenetic abnormality, but it is not a substitute for conventional cytogenetic studies. Cytogenetic response is defined as follows: Complete response: Restoration of a normal karyotype in patients with a documented pre-existing clonal (\\>2 metaphases abnormal) chromosome abnormalities.\n\nPartial response: \\> 50% reduction in the percentage of bone marrow metaphases with only clonal abnormality.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21.","id":"OG000","title":"Arm A (Lenalidomide; Randomization)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.","id":"OG001","title":"Arm B (Lenalidomide + Epoetin Alfa; Randomization)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients randomized to either arm A or arm B who had cytogenetic response data","reportingStatus":"POSTED","timeFrame":"Assessed at baseline and after completion of 16 weeks of treatment","title":"Proportion of Patients With Cytogenetic Response","type":"SECONDARY","unitOfMeasure":"proportion of participants"}